Clinical trial · Interventional
Earliest Stage Treatment of Aktinic Keratosis With Imiquimod 3.75% Cream
NCT04842422CI-TRIAL-00055870completedPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Earliest Stage Treatment of Actinic Keratosis with Imiquimod 3.75% Cream: The study is to demonstrate that Aktinic Keratosis are present before they are clinically visible, i.e. in a subclinical stage. Since on the basis of the research situation, also subclinical AK can proliferate into the dermis, it is possible that with the application of Imiquimod on chronically light-exposed skin, undetected squamous cell carcinoma can be recognized and treated at the same time.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Actinic Keratoses | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Imiquimod 3.75% Cream | Drug | Imiquimod | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Earliest Stage Treatment of Aktinic Keratosis
- interventionNames
- Drug: Imiquimod 3.75% Cream
Primary outcomes (1)
- measure
- immunomodulatory-induced inflammatory reaction
- timeFrame
- two weeks
- description
- Percentage of subjects in whom an immunomodulatory-induced inflammatory reaction occurs on chronically light-exposed uv-damaged facial skin after two weeks.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 50 Years
Show eligibility criteria text
Inclusion * Male and female supposed-healthy volunteer outpatients, age: \> 50 years. * Diagnosis: patients with chronically UV-exposed photodamaged facial skin. * Consent by signing the ICF (Informed Consent Form) Exclusion * Current participation in another clinical trial * Patients who are using topical glucocorticoids on the face. * Known intolerance/hypersensitivity to imiquimod * Pregnant/breastfeeding women * Systemic disease, immunodeficiency
References
Publications (0)
Data not yet available
No reference posted for this study.